Franklin Genomic Advancements ETF

HELX
ETF Ticker

+16.51%

+31.80%

Cboe BZX

Equity

Global

Thematic

The Franklin Genomic Advancements ETF, HELX_US, is an actively managed strategy providing exposure to Global, Thematic Equity. It is listed on the Cboe BZX and has assets under management of $31.6m (as of Aug 31, 2026). The ETF trades in USD and was listed on the exchange on Feb 25, 2020. It has a net expense ratio of 50bps. (All data in USD as of Oct 12, 2026 unless stated.)

The investment process guiding the actively managed Franklin Genomic Advancements ETF targets capital appreciation by investing ≥80% of net assets in equity securities of issuers substantially focused on or positioned to benefit from genomics, spanning DNA sequencing, gene editing, molecular diagnostics, bioinformatics, instrumentation, and related health care sub-industries. The universe is global across market caps, but day-to-day exposure is typically concentrated in U.S. health care. The fund is non-diversified, using bottom-up fundamental research to assess revenue sensitivity to the theme, business-model durability, unit economics, and competitive moats; liquidity screens and position-size limits govern investability. Portfolio construction emphasizes single-issuer caps and sector concentration acceptance consistent with the theme. The manager trims or exits positions upon valuation target attainment, fundamental deterioration, adverse policy shifts, or superior opportunity set. Rebalancing is event-driven, with turnover controlled to preserve capacity and mitigate trading frictions.

ETF Details

Key Facts

Issuer:
Franklin Templeton
AUM:
$31.6m (as of Aug 31, 2026)
Net Expense Ratio:
50 bps
Inception Date:
Feb 25, 2020
Index:
Actively managed strategy
Dividend Frequency:
N/A

Trading

Ticker:
HELX
Exchange:
Cboe BZX
ISIN:
US35473P5200
Trading Currency:
USD
Domicile:
United States

Classification & Risk

Asset Class:
Equity
Asset Region:
Global
Theme:
Thematic
Economic Development:
Global Markets
1 Year Volatility:
24.01%
3 Year Volatility:
22.18%
5 Year Volatility:
24.03%

Performance

TTM Dividend Yield:
0.44% (verify with issuer)
1 Month Performance:
3.20%
3 Month Performance:
5.28%
6 Month Performance:
29.35%
1 Year Performance:
31.80%
3 Year Performance:
52.98%
5 Year Performance:
-13.30%
Investment Proposition

Franklin Genomic Advancements ETF (HELX) targets companies advancing genomics, including DNA sequencing, gene editing, precision diagnostics, and personalized therapeutics. The strategy is actively managed to emphasize firms with differentiated intellectual property, scalable platforms, and commercially relevant pipelines, acknowledging that innovation and regulatory paths rarely move in straight lines. Turnover can be higher than broad-market funds as positions are adjusted around clinical catalysts, competitive data, and funding conditions; the team applies a research-driven approach that seeks exposure to both established enablers and emerging category leaders. Return potential is linked to adoption of genomic technologies across healthcare and adjacent industries, while risk stems from binary clinical outcomes, reimbursement dynamics, and capital-market appetite for growth. In portfolios, HELX fits as a thematic satellite for growth and innovation exposure, a tactical sleeve expressing conviction in life-sciences progress, or a factor-completion tool to balance value-heavy cores. Suitable investors typically pursue long-horizon growth or thematic mandates willing to accept higher volatility. Key risk to monitor: thematic concentration and liquidity in smaller issuers, which can amplify drawdowns during risk-off markets.

ETF Analytics

Fund Discovery

4 Suggestions